HUDSON TECHNOLOGIES INC /NY Stock Compensation Disclosure
Note 12 - Share-Based Compensation
Share-based compensation represents the cost related to share-based awards, typically stock options or stock grants, granted to employees, non-employees, officers and directors. Share-based compensation is measured at grant date, based on the estimated aggregate fair value of the award on the grant date, and such amount is charged to compensation expense on a straight-line basis over the requisite service period. For the years ended December 31, 2025, 2024 and 2023, the share-based compensation expense of $1.1 million, $0.8 million and $2.3 million, respectively, is reflected in Selling, general and administrative expenses in the consolidated income statements.
Share-based awards have historically been made as stock options, and recently also as stock grants, issued pursuant to the terms of the Company’s stock option and stock incentive plans, (collectively, the “Plans”), described below. The Plans may be administered by the Board of Directors or the Compensation Committee of the Board or by another committee appointed by the Board from among its members as provided in the Plans. Presently, the Plans are administered by the Company’s Compensation Committee of the Board of Directors. As of December 31, 2025 there were 6,539,472 shares of the Company’s common stock available under the Plans for issuance for future stock option grants or other stock based awards.
Stock option awards, which allow the recipient to purchase shares of the Company’s common stock at a fixed price, are typically granted at an exercise price equal to the Company’s stock price at the date of grant. Typically, the Company’s stock option awards have vested from immediately to two years from the grant date and have had a contractual term ranging from to ten years. Incentive Stock Options (“ISOs”) granted under the Plans may not be granted at a price less than the fair market value of the common stock on the date of grant (or 110% of fair market value in the case of persons holding 10% or more of the voting stock of the Company). Nonqualified
options granted under the Plans may not be granted at a price less than the fair market value of the common stock. Options granted under the Plans expire not more than ten years from the date of grant (five years in the case of ISOs granted to persons holding 10% or more of the voting stock of the Company).
Effective June 7, 2018, the Company adopted its 2018 Stock Incentive Plan (“2018 Plan”) pursuant to which 4,000,000 shares of common stock were reserved for issuance (i) upon the exercise of options, designated as either ISOs under the Code or nonqualified options, or (ii) as stock, deferred stock or other stock-based awards. ISOs may be granted under the 2018 Plan to employees and officers of the Company. Non-qualified options, stock, deferred stock or other stock-based awards may be granted to consultants, directors (whether or not they are employees), employees or officers of the Company. Stock appreciation rights may also be issued in tandem with stock options. Unless the 2018 Plan is sooner terminated, the ability to grant options or other awards under the 2018 Plan will expire on June 7, 2028.
Effective June 11, 2020, the Company adopted its 2020 Stock Incentive Plan (“2020 Plan”) pursuant to which 3,000,000 shares of common stock were reserved for issuance (i) upon the exercise of options, designated as either ISOs under the Code or nonqualified options, or (ii) as stock, deferred stock or other stock-based awards. ISOs may be granted under the 2020 Plan to employees and officers of the Company. Non-qualified options, stock, deferred stock or other stock-based awards may be granted to consultants, directors (whether or not they are employees), employees or officers of the Company. Stock appreciation rights may also be issued in tandem with stock options. Unless the 2020 Plan is sooner terminated, the ability to grant options or other awards under the 2020 Plan will expire on June 11, 2030.
Effective June 12, 2024, the Company adopted its 2024 Stock Incentive Plan (“2024 Plan”) pursuant to which 3,000,000 shares of common stock were reserved for issuance (i) upon the exercise of options, designated as either ISOs under the Code or nonqualified options, or (ii) as stock, deferred stock or other stock - based awards. ISOs may be granted under the 2024 Plan to employees and officers of the Company. Non - qualified options, stock, deferred stock or other stock - based awards may be granted to consultants, directors (whether or not they are employees), employees or officers of the Company. Stock appreciation rights may also be issued in tandem with stock options. Unless the 2024 Plan is sooner terminated, the ability to grant options or other awards under the 2024 Plan will expire on June 12, 2034.
All stock options have been granted to employees and non-employees at exercise prices equal to or in excess of the market value on the date of the grant.
The Company determines the fair value of share-based awards at the grant date by using the Black-Scholes option-pricing model, and has utilized the “simplified” method, as prescribed by the SEC’s Staff Accounting Bulletin (“SAB”) No.110, Share-Based Payment, to compute expected lives of share based awards. The Company has opted to use the simplified method for stock options because management believes that the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The Company records forfeitures and cancellations as they occur. The following are the weighted-average assumptions:
Year ended | | | |
| |||
December 31, | 2025 | 2024 | 2023 |
| |||
Assumptions |
| |
| |
| | |
Dividend yield |
| 0 | % | 0 | % | 0 | % |
Risk free interest rate |
| 3.61%-4.19 | % | 4.24%-4.29 | % | 3.69%-4.89 | % |
Expected volatility |
| 62.28%-65.67 | % | 77.69%-80.62 | % | 71.73%-94 | % |
Expected lives |
| 2.75-3.5 years |
| 1.5 years |
| 1.5-2.0 years |
The expected stock price volatility is based on the implied volatilities from traded options on our stock, historical volatility of our stock and other factors.
A summary of the activity for the Company’s Plans for the indicated periods is presented below:
| | Weighted | |||
Average | |||||
Stock Options and Stock Appreciation Rights | Shares | Exercise Price | |||
Outstanding at December 31, 2022 |
| 2,390,150 | $ | 1.51 | |
-Cancelled |
| (48,268) | $ | 5.67 | |
-Exercised |
| (296,973) | $ | 2.68 | |
-Granted (1) |
| 602,526 | $ | 10.02 | |
Outstanding at December 31, 2023 |
| 2,647,435 | $ | 3.31 | |
-Cancelled |
| (10,176) | $ | 4.54 | |
-Exercised |
| (39,402) | $ | 7.24 | |
-Granted (2) |
| 135,603 | $ | 10.85 | |
Outstanding at December 31, 2024 | 2,733,460 | $ | 3.63 | ||
-Cancelled | (150,738) | $ | 8.35 | ||
-Exercised | (286,272) | $ | 1.63 | ||
-Granted (3) | 743,439 | $ | 6.26 | ||
Outstanding at December 31, 2025 |
| 3,039,889 | $ | 4.28 | |
| (1) | Options to purchase 584,826 shares were granted in 2023, of which options to purchase 337,727 shares vested immediately in 2023 and the remainder vested 50% immediately and 50% one year after the date of the grants. In addition, 17,700 stock appreciation rights were granted in January 2023 with a - month vesting period. |
| (2) | Options to purchase 135,603 shares were granted in 2024, of which options to purchase 111,975 shares vested immediately in 2024 and the remainder vested 50% immediately and 50% one year after the date of the grants. |
| (3) | Options to purchase 675,939 shares were granted in 2025, of which options to purchase 68,490 shares vested immediately in 2025; 391,140 shares are subject to cliff vesting on December 31, 2027, contingent upon the achievement of performance-based metrics; and the remaining 216,309 shares will vest 50% on the first anniversary of the grant and the remaining 50% on the second anniversary. In addition, 67,500 stock appreciation rights were granted in 2025 with - year vesting period. |
The following is the weighted average contractual life in years and the weighted average exercise price at December 31, 2025 and 2024 of:
| | Weighted | | ||||
Average | |||||||
Remaining | Weighted | ||||||
Number of | Contractual | Average | |||||
December 31, 2025 | Options | Life (Years) | Exercise Price | ||||
Options outstanding and vested |
| 2,564,699 |
| 1.94 | $ | 3.87 | |
| | Weighted | | ||||
Average | |||||||
Remaining | Weighted | ||||||
Number of | Contractual | Average | |||||
December 31, 2024 | Options | Life(Years) | Exercise Price | ||||
Options outstanding and vested |
| 2,713,522 |
| 3.26 | $ | 3.55 | |
The intrinsic values of options outstanding at December 31, 2025 and 2024 are $10.0 million and $8.6 million, respectively.
The intrinsic value of options unvested at December 31, 2025 and 2024 are $0.2 million and $0.0 million, respectively. As of December 31, 2025 there was $0.0 million of unrecognized share based compensation expense related to non-vested options.
The intrinsic values of options vested and exercised during the years ended December 31, 2025, 2024 and 2023 were as follows:
| 2025 | | 2024 | | 2023 | ||||
Intrinsic value of options vested | $ | 126,732 | $ | — | $ | 2,886,080 | |||
Intrinsic value of options exercised | $ | 1,815,575 | $ | 184,282 | $ | 2,565,056 | |||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 16, 2026 | Showing above |
| 2024 | Mar 12, 2025 | |
| 2023 | Mar 14, 2024 | |
| 2022 | Mar 14, 2023 | |
| 2021 | Mar 24, 2022 | |
| 2020 | Mar 12, 2021 | |
| 2019 | Mar 13, 2020 | |
| 2018 | Mar 15, 2019 | |
| 2017 | Mar 16, 2018 | |
| 2016 | Mar 10, 2017 | |
| 2015 | Mar 11, 2016 | |
About Stock Compensation Disclosures
Stock-based compensation disclosures detail the equity awards granted to employees and executives — including stock options, restricted stock units (RSUs), and performance shares — along with the valuation methods and assumptions used to expense them. This section reveals the true cost of talent retention and the alignment between management incentives and shareholder interests.
Key signals: total unrecognized compensation expense and its expected recognition period signal future earnings headwinds from already-granted awards. For stock options, examine Black-Scholes assumptions — expected volatility, risk-free rate, and expected term — as understating any of these reduces reported compensation expense. Compare stock compensation expense as a percentage of revenue against peers to assess dilution cost. Watch vesting schedules for acceleration clauses tied to change-of-control events. Performance-based awards with undemanding targets may indicate weak governance. Add back stock compensation to operating cash flow to calculate a more conservative free cash flow figure.